Propranolol added to standard chemoradiation for esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial studies whether adding propranolol (a common blood-pressure/heart medication) to standard chemotherapy and radiation can improve outcomes for people with esophageal adenocarcinoma. You would start propranolol around the time of treatment, with careful heart monitoring and study follow-up.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are receiving standard chemoradiation (chemo plus radiation) for esophageal adenocarcinoma
- Your health status is good enough (ECOG 0–1)
- You can swallow and keep taking pills by mouth, or you can take them through a feeding tube if swallowing is hard
- If you could become pregnant: pregnancy test is negative and you agree to reliable birth control
- You can understand the study and sign the consent form before any study procedures
- You do not have health problems that make beta-blockers unsafe (like certain heart rhythm issues, very low blood pressure, severe asthma/COPD, or uncontrolled diabetes)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy drugs given together with radiation therapy, followed by additional chemotherapy, for newly diagnosed adenocarcinoma (a type of cancer) in the esophagus or where the esophagus meets the stomach. The goal is to shrink the tumor and improve survival.
This trial tests whether adding propranolol (a common blood-pressure/heart medicine) can improve outcomes when used with pembrolizumab plus standard chemotherapy. It is for people with advanced esophageal or gastroesophageal junction adenocarcinoma that cannot be removed with surgery.
This trial tests adding a beta-blocker (propranolol) to a combination of immunotherapy (sintilimab) and standard chemotherapy for people with advanced non-small cell lung cancer that hasn't been treated before. The goal is to see if this new triple treatment helps shrink tumors better than chemo-immunotherapy alone.
This trial tests whether adding a blood-pressure medicine (propranolol) to a combination of two immunotherapy drugs plus chemotherapy is safe and works better for locally advanced colon cancer that has not spread. It's for tumors that are pMMR/MSS, which are less likely to respond to immunotherapy alone, so the propranolol may help the immune system fight the cancer.
This trial studies whether proton therapy can better treat early-to-mid stage esophagus cancer while aiming to reduce side effects to nearby organs. Proton therapy uses a targeted type of radiation, and participants are also checked to be eligible for curative surgery.
This trial tests a new treatment for esophageal cancer that has not spread too far. It combines proton beam radiation (a precise type of radiation) with chemotherapy and immunotherapy (drugs that help your immune system fight cancer). The goal is to see if this combination is safe and effective.
Hear when a new Esophageal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.